Hosted on MSN1mon
Oruka Therapeutics inks exclusive license deal with Paragon
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing ... antibodies for at least five years within the same field. Oruka Therapeutics is obligated to pay Paragon ...
Nasdaq29d
Insider Purchase: 10% owner at $ORKA Buys 88,794 Shares
Healthcare Capital Partners III, L.P. Venrock, a 10% owner of $ORKA, bought 88,794 shares of the company on 02-14-2025 for an estimated $1,015,803. This trade was ...
Nasdaq8d
Oruka Therapeutics Reports 2024 Financial Results and Progress on Psoriasis Pipeline Including ORKA-001 and ORKA-002
Another promising candidate, ORKA-002, which targets IL-17A/F ... potential to offer best-in-class treatments in the psoriasis field. Successful go-public transaction, raising over $475 million ...
Morningstar8d
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a ...